U.S. stocks finished sharply lower Thursday, November 19, 2026, as enthusiasm surrounding Anthropic’s (ANT, $97.17, +17.07%) public debut failed to sustain an early technology rally.. The Dow fell 1,101.11 points, while the S&P 500, Nasdaq Composite and Russell 2000 each lost more than 2%, according to the supplied closing-market snapshot. The reversal unfolded as many reassessed artificial intelligence valuations, semiconductor export risks and an economic backdrop marked by slower regional manufacturing growth and persistent price pressures. Anthropic (ANT) opened well above its $83 offering price reaching $111.68, but that company-specific enthusiasm did not translate into a durable advance across the broader market.
Closing Market Performance
| Index | Closing level | Point change | Daily change |
|---|---|---|---|
| S&P 500 | 7,175.83 | -147.80 | -2.02% |
| Dow Jones Industrial Average | 49,097.06 | -1,101.11 | -2.19% |
| Nasdaq Composite | 23,879.20 | -550.69 | -2.25% |
| Russell 2000 | 2,654.67 | -59.64 | -2.20% |
The losses extended beyond large technology stocks. The Russell 2000’s 2.20% decline placed smaller companies alongside the major benchmarks in the selloff, while the Cboe Volatility Index rose 16.33% to 28.56. Together, those moves pointed to a broad retreat from risk rather than an isolated pullback in a handful of AI-related shares.
Anthropic’s IPO Pop Fails to Lift the Broader AI Trade
Anthropic (ANT), the company behind Claude, began trading at $111.50 per share, approximately 34.3% above its $83 initial public offering price. The offering raised approximately $81 billion before any additional proceeds from the underwriters’ option. The debut initially offered a potential catalyst for an AI rebound. Instead, the major indexes turned sharply lower around the start of trading in Anthropic (ANT), reversing substantial early gains. The Nasdaq Composite had risen as much as 2% earlier in the session before the market’s direction changed. The distinction matters: demand for a newly listed AI company does not necessarily signal renewed confidence in the entire AI investment cycle. Thursday’s trading suggested many remained selective about valuations, infrastructure spending and the timing of future profits, even while welcoming a major new public listing. The timing of the reversal, however, does not establish that the IPO alone caused the broader decline.
Macroeconomic Report: Slower Factory Growth Meets Stubborn Price Pressure
Philadelphia Fed manufacturing activity loses momentum
The Philadelphia Federal Reserve’s November Manufacturing Business Outlook Survey delivered a mixed economic message. Regional manufacturing continued to expand, but growth became considerably less widespread. Key readings included:
- General business activity fell to 6.3 from 20.9 in October.
- The prices paid index increased to 58.2 from 43.2.
- The prices received index rose to 47.0 from 40.1
A positive activity reading still indicates that more surveyed manufacturers reported improvement than deterioration. However, the sharp decline in the headline index, alongside rising input and selling-price measures, presented an uncomfortable combination of softer momentum and continuing inflation pressure. These are regional survey measures, not a direct reading of nationwide output or consumer inflation. For the interest-rate outlook, that combination complicates the picture. Slower growth can strengthen the argument for easier policy, but persistent price pressure works in the opposite direction. The report therefore offered no simple case for expecting both rapid disinflation and stronger economic activity.
Jobless claims edge higher without signaling a layoff surge
Initial unemployment claims totaled 203,000 for the week ended November 14, up 1,000 from the previous week and above the reported consensus forecast of 197,000. Continuing claims increased 70,000 to 1.76 million. The figures pointed to modest labor-market softening rather than an abrupt wave of layoffs. Rising continuing claims nevertheless added a cautionary note about how quickly people receiving benefits were returning to work. Combined with the manufacturing survey, the releases left many weighing economic resilience against signs of cooling momentum.
AMD Faces Renewed Scrutiny Over China Exposure
Advanced Micro Devices (AMD) came under pressure after Hunterbrook disclosed a short position and published allegations involving the company’s exposure to China and U.S. export restrictions. Shares fell as much as approximately 9% during the session, according to the supplied coverage. That was an intraday move, not a verified closing return. The report alleged that newer firmware continued reaching a blacklisted Chinese server manufacturer and warned that tighter export rules could threaten business tied to the region. These remain allegations, not established regulatory findings. The coverage said the claims had not been independently verified and that Advanced Micro Devices (AMD) had not immediately responded to a request for comment. The episode highlighted another risk for semiconductor valuations: strong AI demand does not eliminate uncertainty over export licenses, distribution channels and access to overseas customers.
Walmart Raises Its Outlook as Digital Sales Expand
Walmart (WMT) offered a more constructive corporate update, reporting quarterly revenue growth of 5.2% and raising its full-year sales and adjusted earnings outlook. Global e-commerce sales increased 17%, while U.S. e-commerce sales rose 23%. The retailer’s updated guidance included:
- Full-year net sales growth of 4.9% to 5.2%, compared with its previous forecast of 4% to 5%.
- Adjusted earnings per share of $2.84 to $2.89, up from $2.80 to $2.87.
- Adjusted operating income growth of 8% to 8.6%, compared with 7% to 8.5% previously.
Walmart’s (WMT) results suggested consumers continued spending, particularly where price and convenience aligned. U.S. comparable sales excluding fuel increased 2.9%, while the company reported price reductions on nearly 8,000 products. Still, the earnings outlook implied a more restrained holiday-quarter profit picture than the headline guidance increase alone might suggest. The broader economic takeaway was not that household pressures had disappeared. Rather, Walmart (WMT) demonstrated how value positioning, delivery services and digital growth can support sales while customers remain sensitive to living costs
Cybersecurity: Strong Earnings Contrast With Vendor-Breach Concerns
Palo Alto Networks posts an earnings beat and announces an AI deal
Palo Alto Networks (PANW) reported fiscal first-quarter revenue of $3.44 billion, up 39% year over year and above the cited $3.31 billion estimate. Adjusted earnings of $1.05 per share exceeded the $0.97 forecast. The company also raised its fiscal 2027 revenue outlook to $14.52 billion to $14.57 billion and announced an agreement to acquire privately held Applied Compute in a stock transaction valued at $4.5 billion. Shares opened approximately 8% higher Thursday, although the supplied report did not establish a closing gain. The results provided a company-specific counterpoint to the broader technology selloff, showing that stronger operating performance could still attract demand even as enthusiasm for AI-related stocks became less uniform.
Financial companies report exposure through third-party providers
JPMorgan Chase (JPM), Visa (V) and Mastercard (MA) disclosed incidents involving third-party providers and limited customer information, including certain email addresses and, in some cases, names. The companies said their own systems were not affected and that payment or card data had not been exposed. The important distinction was between compromised vendor-held information and a breach of core banking or payment infrastructure. The reported exposure nevertheless created potential phishing risks and reinforced the importance of security controls across outside service providers.
Biotechnology: Takeover Speculation and New Financing Drive Headlines
Insmed jumps on reported Sanofi interest
Insmed (INSM) rose approximately 20.58% at the closed of trading today after a report, attributed to Bloomberg, said Sanofi (SNY) was considering a takeover. Neither company confirmed negotiations, and the coverage said both declined to comment.. The strategic interest centered on Insmed’s (INSM) commercial growth, including Brinsupri. The company had raised its 2026 sales guidance for that product to $1.35 billion to $1.4 billion, according to the report. Any acquisition remained speculative, with no announced agreement or confirmed transaction terms.
SELLAS prices a $150 million offering
SELLAS Life Sciences Group (SLS) announced the pricing of an underwritten public offering of 11,538,462 common shares at $13 per share, targeting approximately $150 million in gross proceeds before fees and expenses.. The company also granted underwriters a 30-day option to purchase up to 1,730,769 additional shares. The offering was expected to close November 20, subject to customary conditions. The financing would add capital, while the issuance of additional shares would dilute existing ownership.
Treasury Yields, Oil, Gold and Bitcoin
| Asset or indicator | Displayed level | Displayed daily change |
|---|---|---|
| 10-year Treasury yield | 5.05% | -0.01 percentage point |
| Cboe Volatility Index | 28.56 | +16.33% |
| December crude oil futures | $83.13 per barrel | +1.00% |
| Gold | $3,660.00 per ounce | -2.19% |
| Bitcoin | $61,946.20 | -0.50% |
The cross-asset picture was uneven. Treasury yields edged lower, but gold also declined, while oil advanced. That combination underscored that Thursday’s equity selloff did not produce a uniform rally across assets commonly associated with defensive positioning.
Market Takeaway
Thursday’s defining development was the gap between enthusiasm for a high-profile AI debut and confidence in the broader stock market. Anthropic (ANT) attracted a substantial opening premium, yet all four major U.S. equity benchmarks in the supplied closing snapshot lost more than 2%. At the same time, the economic releases offered little relief from the central policy tension: growth was cooling in parts of the economy, but manufacturing price pressures remained elevated. Strong company updates, including those from Walmart (WMT) and Palo Alto Networks (PANW), provided selective bright spots rather than enough support to reverse the market-wide retreat.
Updates From the VP Watchlist
Amwell® (NYSE: AMWL)
Amwell® (NYSE: AMWL), a leading provider of technology-enabled care, closed at $10.69. Amwell reported after the close Nov. 3 the company’s Third Quarter 2026 Highlights: Recorded Total Revenue of $49.0 million, exceeding the previously provided financial guidance range for Q3, Achieved subscription revenue of $23.9 million, Recorded Amwell Medical Group (“AMG”) visit revenue of $23.7 million, Reported gross margin of 53%, Net loss was ($11.0) million, compared to ($9.6) million in the second quarter of 2026, Adjusted EBITDA of ($3.6) million compared to ($1.2) million in the second quarter of 2026, & Total visits on the platform were 0.8 million. Financial Outlook: The Company is raising its 2026 revenue outlook, and adjusted EBITDA outlook, and reaffirming its AMG visit guidance., Revenue in the range of $204 million to $206 million increased from $200 million to $205 million. AMG visits between 1.32 million and 1.37 million Adjusted EBITDA in the range between ($8) million to ($7) million increased from ($9) million to ($7) million.
The Company also provided financial guidance for Q4 2026 Revenue and adjusted EBITDA:
- Q4 revenue in the range of $48 million to $50 million
- Q4 adjusted EBITDA expected to in the range of $0 million to $1 million.
The Company also reiterated its objective to achieve positive cash flow from operations in the fourth quarter of 2026.
Serina Therapeutics (NYSE: SER)
Serina Theraeuptics (NYSE: SER, $1.20) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
On Thursday, November 12, Serina reported its financial results for the third quarter ended September 30, 2026, along with key business updates. Steve Ledger, Chief Executive Officer of Serina stated, “We are excited about the achievement of important clinical milestones for SER-252 in Parkinson’s disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development. Dosing in Cohort 2 is currently underway and focuses on demonstrating SER-252’s potential as a differentiated treatment option for patients with advanced Parkinson’s disease to improve the significant challenge of consistent symptom control.”
On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.
Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX, $6.12), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today, ( Nov. 10), announced its financial results for the third quarter of 2026. Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We remain on track to report interim results from the Phase 2b portion of the RESOLVE trial in December, and were pleased to announce in mid-October that we had reached our target enrollment of 120 patients. We are very encouraged by the Phase 1b/2a data from the open-label portion of the RESOLVE trial that was reported this quarter, which includes 36- and 52-week data from our highest dosing cohorts. We believe this data provides further evidence of the observed durable treatment effects of EP-104GI in EoE patients, seen in previous cohorts. In total, we have observed 64% of patients remaining in clinical remission over this 52-week period in addition to clinically meaningful histologic improvements. With cash runway into the second half of 2028, we believe we remain well funded to execute on our upcoming milestones for our EoE program.”
EPRX gained a significant new Wall Street endorsement Monday as RBC Capital Markets initiated coverage with an Outperform rating, a Speculative Risk designation and a $14 price target. The research makes a bullish case for EP-104GI, the company’s investigational treatment for eosinophilic esophagitis, ahead of an expected December clinical readout. Against the $6.89 reference price in RBC’s report, the target implies approximately 103% upside, not a forecast of where shares must trade. The attraction is unusually straightforward for biotechnology: take a familiar anti-inflammatory medicine, deliver it precisely into diseased tissue and attempt to make its benefits last long enough to change the treatment routine. If that approach succeeds, Eupraxia would offer more than another prescription for a chronic disease. It could offer a different calendar. RBC analyst Douglas Miehm’s November 9 initiation argues that EP-104GI could occupy a differentiated position in eosinophilic esophagitis, commonly called EoE, through localized delivery and the potential for once-yearly administration. The next major test is whether encouraging early results translate into convincing evidence against a vehicle control in the Phase 2b RESOLVE study.
EPRX announced (Oct. 15) that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target. “This is a significant milestone for the RESOLVE trial and the development of EP-104GI as a potential treatment option in EoE” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “We look forward to our interim analysis in December where we will be reporting on symptoms, histologic findings and safety in the first 60 patients in Phase 2b to reach 6 months. Data will also be available on the patients at 3, 9- and 12-month timepoints giving a fulsome interim look at the RESOLVE Trial”.
Modular Medical, Inc. (NASDAQ: MODD)
Modular Medical, Inc. (NASDAQ: MODD, $1.905, +4.67%), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, is pursuing a different proposition: make insulin delivery less demanding for the people who must manage it every day. On November 19, Modular Medical announced that it has entered into agreements with the remaining two of the nation’s three largest pharmacy benefit managers (“PBMs”) for its Pivot tubeless patch pump. With these agreements, Modular Medical has now entered into agreements with all three of the nation’s largest PBMs, whose networks collectively cover more than 182 million lives and process approximately 80% of U.S. prescription claims.1 Coverage for any individual patient remains subject to the formulary decisions and benefit design of the applicable health plan or plan sponsor.
New patient research announced November 9 gives that strategy a persuasive commercial foundation. In a three-phase study conducted with Thrivable involving more than 540 people with Type 1 or Type 2 diabetes, approximately nine out of 10 surveyed multiple daily injection users said they would consider a simpler insulin delivery option. In the final-phase survey of 303 participants, 48.5% expressed strong interest in the company’s Pivot tubeless patch pump. The distinction matters. General enthusiasm for something easier is not the same as product-specific interest, and neither is a prescription. Still, the findings suggest Modular Medical is addressing a recognizable problem rather than inventing one for the benefit of a presentation deck. For many following MODD, the emerging opportunity centers on one word: simplicity. The company has already moved beyond the purely developmental stage. Its annual report documents U.S. Food and Drug Administration clearance for Pivot in April 2026, followed by commercial availability and initial patient shipments in June. The question now is whether a differentiated product, improving access and more focused patient education can turn that regulatory foundation into a repeatable commercial business.
MODD announced (Oct. 27) that it has received a positive decision from its notified body regarding certification of its quality management system under ISO 13485:2016. The notified body is designated under the European Union Medical Device Regulation (“MDR”).
Alphabet (NASDAQ: GOOGL $272.66, -3,46%)
Alphabet (NASDAQ: GOOGL, GOOG) is confronting an expensive paradox: Artificial intelligence is bringing more activity to Google while making the economics of that activity harder to predict. Yet the latest results offer a more constructive interpretation than a simple obituary for search. Third-quarter revenue increased 25% to $127.6 billion. Operating income climbed 30% to $40.6 billion. Google Cloud revenue more than doubled. Those are unusual credentials for a company supposedly being escorted toward technological irrelevance. At the close on Thursday, Alphabet shares traded at $283.82, following a 12.64% decline, many are clearly demanding more proof and fewer architectural renderings of future data centers. That skepticism is understandable. But the opportunity lies in distinguishing a difficult transition in monetization from a collapse in demand. Google’s problem is not that people have stopped asking questions. According to management, its year-over-year search-query growth reached its highest rate in five years during the third quarter. The more consequential question is how quickly Google can turn its expanding AI audience into attractive, durable cash flow. Wall Street has little patience for a renovation when the contractor’s estimate begins with a trillion.
Space Exploration Technologies Corp. (SPCX, $138.43, -3.53%)
SpaceX-related coverage is orbiting three themes: a possible combination with Tesla, an expanding AI infrastructure footprint, and robust Starlink demand, because apparently conquering one industry at a time is inefficient. Reported third-quarter revenue totaled $14.6 billion, while management projected first-quarter 2027 revenue of $33 billion–$37 billion, a range with little apparent interest in remaining earthbound.
The Sources
- U.S. stock market session overview and Anthropic (ANT) trading debut
- November 19 market updates, unemployment claims and economic releases
- Anthropic (ANT) IPO pricing, offering details and public debut
- Advanced Micro Devices (AMD) short-seller allegations and China exposure
- Walmart (WMT) quarterly results and updated full-year outlook
- JPMorgan Chase (JPM), Visa (V) and Mastercard (MA) third-party cybersecurity incident
- SELLAS Life Sciences Group (SLS) $150 million public offering announcement
- Insmed (INSM) trading reaction to reported Sanofi (SNY) takeover interest
- Palo Alto Networks (PANW) fiscal first-quarter earnings and Applied Compute agreement
- Federal Reserve Bank of Philadelphia: November 2026 Manufacturing Business Outlook Survey
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.

Daily Market Summary – Sept. 23, 2026: Stocks Retreat as Treasury Yields Surge and Inflation Risks Reprice -( $AMWL $AMZN $DOCS $DIS $EPRX $IONQ $MCD $MODD $NVDA $SER $TSLA $WOR $YSG )